Published online before print August 9, 2004, doi: 10.1161/01.CIR.0000138935.17503.35
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Circulation. 2004;110:790-795.)
© 2004 American Heart Association, Inc.
Original Articles |
Randomized, Double-Blind, Placebo-Controlled Trial of Oral Sirolimus for Restenosis Prevention in Patients With In-Stent Restenosis
The Oral Sirolimus to Inhibit Recurrent In-stent Stenosis (OSIRIS) Trial
From the Deutsches Herzzentrum München, Klinik an der TU München (J.H., A.K., J.M., C.G., J.P., G.P.-M., A.S.), Institut für Klinische Chemie, Klinikum Großhadern, Ludwig-Maximilians-Universität (M.V.), I. Medizinische Klinik des Klinikums rechts der Isar, Technische Universität (D.Z., H.S., J.D.), and II. Medizinische Klinik des Klinikums rechts der Isar, Technische Universität (U.H.), Munich, and the Medizinische Klinik I des Klinikums Garmisch-Partenkirchen, Garmisch-Partenkirchen (F.D.), Germany.
Correspondence to Dr Jörg Hausleiter, Deutsches Herzzentrum, Lazarettstrasse 36, 80636 München, Germany. E-mail hausleiter{at}dhm.mhn.de
Received April 1, 2004; revision received June 22, 2004; accepted June 23, 2004.
Background— Despite recent advances in interventional cardiology, including the introduction of drug-eluting stents for de novo coronary lesions, the treatment of in-stent restenosis (ISR) remains a challenging clinical issue. Given the efficacy of systemic sirolimus administration to prevent neointimal hyperplasia in animal models and to halt and even reverse the progression of allograft vasculopathy, the aim of the present double-blind, placebo-controlled study was to evaluate the efficacy of a 10-day oral sirolimus treatment with 2 different loading regimens for the prevention of recurrent restenosis in patients with ISR.
Methods and Results— Three hundred symptomatic patients with ISR were randomly assigned to 1 of 3 treatment arms: placebo or usual-dose or high-dose sirolimus. Patients received a cumulative loading dose of 0, 8, or 24 mg of sirolimus 2 days before and the day of repeat intervention followed by maintenance therapy of 2 mg/d for 7 days. Angiographic restenosis at 6-month angiography was the primary end point of the study. Restenosis was significantly reduced from 42.2% to 38.6% and to 22.1% in the placebo, usual-dose, and high-dose sirolimus groups, respectively (P=0.005). Similarly, the need for target vessel revascularization was reduced from 25.5% to 24.2% and to 15.2% in the placebo, usual-dose, and high-dose groups, respectively (P=0.08). The sirolimus blood concentration on the day of the procedure correlated significantly with the late lumen loss at follow-up (P<0.001).
Conclusions— In patients with ISR, an oral adjunctive sirolimus treatment with an intensified loading regimen before coronary intervention resulted in a significant improvement in the angiographic parameters of restenosis.
Key Words: restenosis • stents • trials • angioplasty
Related Article:
Circulation 2004 110: 765.
This article has been cited by other articles:
 |
|
 |
|
  S. Kufner, J. Hausleiter, G. Ndrepepa, S. Schulz, O. Bruskina, R. A. Byrne, M. Fusaro, A. Kastrati, A. Schomig, J. Mehilli, et al. Long-Term Risk of Adverse Outcomes and New Malignancies in Patients Treated With Oral Sirolimus for Prevention of Restenosis J. Am. Coll. Cardiol. Intv., November 1, 2009; 2(11): 1142 - 1148. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Hegner, M. Lange, A. Kusch, K. Essin, O. Sezer, E. Schulze-Lohoff, F. C. Luft, M. Gollasch, and D. Dragun mTOR Regulates Vascular Smooth Muscle Cell Differentiation From Human Bone Marrow-Derived Mesenchymal Progenitors Arterioscler Thromb Vasc Biol, February 1, 2009; 29(2): 232 - 238. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G. Nuhrenberg, N. Langwieser, J. B.K. Schwarz, Y. Hou, P. Frank, F. Sorge, S. Matschurat, S. Seidl, A. Kastrati, A. Schomig, et al. EMAP-II downregulation contributes to the beneficial effects of rapamycin after vascular injury Cardiovasc Res, February 1, 2008; 77(3): 580 - 589. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. J.W. Wallitt, M. Jevon, and P. I. Hornick Therapeutics of Vein Graft Intimal Hyperplasia: 100 Years On Ann. Thorac. Surg., July 1, 2007; 84(1): 317 - 323. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C P Chung, A Oeser, I Avalos, P Raggi, and C M Stein Cardiovascular risk scores and the presence of subclinical coronary artery atherosclerosis in women with systemic lupus erythematosus Lupus, September 1, 2006; 15(9): 562 - 569. [Abstract] [PDF]
|
|
|
|
 |
|
 A. E. Rodriguez, J. F. Granada, M. Rodriguez-Alemparte, C. F. Vigo, J. Delgado, C. Fernandez-Pereira, A. Pocovi, A. M. Rodriguez-Granillo, D. Schulz, A. E. Raizner, et al. Oral Rapamycin After Coronary Bare-Metal Stent Implantation to Prevent Restenosis: The Prospective, Randomized Oral Rapamycin in Argentina (ORAR II) Study J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1522 - 1529. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Roy-Chaudhury, V. P. Sukhatme, and A. K. Cheung Hemodialysis Vascular Access Dysfunction: A Cellular and Molecular Viewpoint J. Am. Soc. Nephrol., April 1, 2006; 17(4): 1112 - 1127. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Mehilli, A. Kastrati, R. Wessely, A. Dibra, J. Hausleiter, B. Jaschke, J. Dirschinger, A. Schomig, and for the Intracoronary Stenting and Angiographic Re Randomized Trial of a Nonpolymer-Based Rapamycin-Eluting Stent Versus a Polymer-Based Paclitaxel-Eluting Stent for the Reduction of Late Lumen Loss Circulation, January 17, 2006; 113(2): 273 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Zohlnhofer, J. Hausleiter, A. Kastrati, J. Mehilli, C. Goos, H. Schuhlen, J. Pache, G. Pogatsa-Murray, U. Heemann, J. Dirschinger, et al. A Randomized, Double-Blind, Placebo-Controlled Trial on Restenosis Prevention by the Receptor Tyrosine Kinase Inhibitor Imatinib J. Am. Coll. Cardiol., December 6, 2005; 46(11): 1999 - 2003. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A H Gershlick Is there any place for oral anti-restenotic treatment in the era of drug eluting stents? Heart, November 1, 2005; 91(11): 1377 - 1379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A E Rodriguez, M Rodriguez Alemparte, C F Vigo, C Fernandez Pereira, C Llaurado, D Vetcher, A Pocovi, and J Ambrose Role of oral rapamycin to prevent restenosis in patients with de novo lesions undergoing coronary stenting: results of the Argentina single centre study (ORAR trial) Heart, November 1, 2005; 91(11): 1433 - 1437. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Schomig, A. Kastrati, and R. Wessely Prevention of Restenosis by Systemic Drug Therapy: Back to the Future? Circulation, November 1, 2005; 112(18): 2759 - 2761. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hausleiter, A. Kastrati, R. Wessely, A. Dibra, J. Mehilli, T. Schratzenstaller, I. Graf, M. Renke-Gluszko, B. Behnisch, J. Dirschinger, et al. Prevention of restenosis by a novel drug-eluting stent system with a dose-adjustable, polymer-free, on-site stent coating Eur. Heart J., August 1, 2005; 26(15): 1475 - 1481. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. W. O'Neill, S. R. Dixon, and C. L. Grines The year in interventional cardiology J. Am. Coll. Cardiol., April 5, 2005; 45(7): 1117 - 1134. [Full Text] [PDF]
|
|
|
|
|
|
R. Wessely, J. Hausleiter, C. Michaelis, B. Jaschke, M. Vogeser, S. Milz, B. Behnisch, T. Schratzenstaller, M. Renke-Gluszko, M. Stover, et al. Inhibition of Neointima Formation by a Novel Drug-Eluting Stent System That Allows for Dose-Adjustable, Multiple, and On-Site Stent Coating Arterioscler Thromb Vasc Biol, April 1, 2005; 25(4): 748 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kastrati, J. Mehilli, N. von Beckerath, A. Dibra, J. Hausleiter, J. Pache, H. Schuhlen, C. Schmitt, J. Dirschinger, A. Schomig, et al. Sirolimus-Eluting Stent or Paclitaxel-Eluting Stent vs Balloon Angioplasty for Prevention of Recurrences in Patients With Coronary In-Stent Restenosis: A Randomized Controlled Trial JAMA, January 12, 2005; 293(2): 165 - 171. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Oral Sirolimus for Restenosis Prevention? Journal Watch Cardiology, October 22, 2004; 2004(1022): 6 - 6. [Full Text]
|
|